Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,220.28 +5.26 (+0.43%)
Official Closing Price Updated: 6:30 PM EDT, Aug 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style? ↗
VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better. 
Via The Motley Fool
Topics ETFs
News headline image
Eli Lilly Escalates Retatrutide Fight, Reports 200-Plus Illegal Sellers to Authorities ↗
Eli Lilly filed six lawsuits against U.S. entities for illegally selling unapproved retatrutide, warning consumers of serious health risks. 
Via Benzinga
Topics Law Enforcement Lawsuit
News headline image
1 Vanguard ETF That Outperforms the S&P 500 and Still Has Room to Run ↗
It has proven to be a market-beater in more years than not. 
Via The Motley Fool
Topics ETFs Stocks
Eli Lilly (NYSE:LLY) Shows a Strong Technical Breakout Setup ↗
Via Chartmill
Eli Lilly (NYSE:LLY) Pairs High Growth Momentum with a Defined Breakout Setup ↗
Via Chartmill
News headline image
The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
News Provided by USA News Group on behalf of Conexeu Sciences Inc. 
From USA News Group
Via GlobeNewswire
News headline image
5 Revealing Analyst Questions From Eli Lilly’s Q2 Earnings Call
Eli Lilly’s second quarter was marked by a positive market reaction, despite the company missing Wall Street’s revenue expectations. Management credited grow... 
Via StockStory
Topics Earnings
News headline image
Better Buy: Eli Lilly vs. Novo Nordisk ↗
Novo Nordisk is playing catch-up in the GLP-1 race. 
Via The Motley Fool
News headline image
Absci Q2 Earnings Call Highlights ↗
Absci (NASDAQ:ABSI) outlined progress in its clinical program for ABS-201, a prolactin receptor-targeting antibody being studied for pattern hair loss and planned for development in endometriosis,... 
Via MarketBeat
Topics Artificial Intelligence Earnings
News headline image
2 Stocks I Think Are Hands-Down Better Picks Than SpaceX Right Now ↗
SpaceX has attractive prospects, but the market has already factored that into its share price. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Omada Health Touts Record Q2 as GLP-1 Demand Fuels Growth Strategy ↗
Omada Health (NASDAQ:OMDA) highlighted record second-quarter revenue and margin performance at the Canaccord Genuity Growth Conference, while outlining its strategy to expand across cardiometabolic... 
Via MarketBeat
News headline image
2 S&P 500 Stocks with Exciting Potential and 1 We Ignore
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ... 
Via StockStory
Topics Stocks
News headline image
Why Eli Lilly Topped the Market Today ↗
One of its more popular products just got the green light from a major national regulator. 
Via The Motley Fool
News headline image
Eli Lilly Upgraded, Best Buy Downgraded: Updated Rankings on Top Blue-Chip Stocks ↗
During these busy times, it pays to stay on top of the latest profit opportunities. And today’s blog post should be a great place to start. 
Via InvestorPlace
News headline image
Better GLP-1 Stock to Buy: Eli Lilly or Viking Therapeutics? ↗
It's not much of a rivalry yet. 
Via The Motley Fool
News headline image
iShares Global Healthcare ETF vs State Street SPDR Biotech ETF. Which Healthcare-Focused Fund Will Bring You Profits in 2026 and Beyond? ↗
XBI surged 80% in one year but endured a 54% drawdown, while IXJ delivered steadier gains with half volatility and a 1.4% dividend. 
Via The Motley Fool
Topics ETFs
News headline image
Eli Lilly and Company Q2 Earnings Call Highlights ↗
Eli Lilly and Company (NYSE:LLY) reported 48% revenue growth in the second quarter of 2026, driven primarily by continued demand for its cardiometabolic medicines MOUNJARO and ZEPBOUND, while raising... 
Via MarketBeat
Topics Earnings
News headline image
Vanguard Health Care ETF vs State Street XLV: Which ETF Is the Better Buy for Investors in 2026? ↗
XLV's concentrated 60-stock portfolio beat VHT's broader 423 holdings over five years, though VHT delivered stronger 1-year returns. 
Via The Motley Fool
Topics ETFs Economy
News headline image
Eli Lilly's Timing of the FDA Filing of Its Next Weight-Loss Drug Is Now Official -- and Novo Nordisk Has a Problem ↗
Can anyone take the top spot away from Eli Lilly in the anti-obesity area? 
Via The Motley Fool
News headline image
Pfizer's Next Weight-Loss Weapon: How Berobenatide Stacks Up Against Novo Nordisk's Wegovy and Eli Lilly's Zepbound ↗
Berobenatide is one of the keys to Pfizer's future. 
Via The Motley Fool
News headline image
Jim Cramer Calls This Industrial Stock ‘Sensational’ And Ameriprise Financial ‘Fantastic’ ↗
Jim Cramer praises Lockheed Martin and Ameriprise Financial, advises against Cipher Digital. Eli Lilly to acquire AtaiBeckley for $3.8B. 
Via Benzinga
News headline image
Every S&P 500 Sector ETF Ranked by How Much It Actually Depends on Just 3 Stocks ↗
Sector ETFs give the impression of diversification. Most of them don't have it. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
News headline image
Prediction: This Unstoppable Vanguard ETF Will Crush the S&P 500 in the Remainder of 2026 ↗
Some of America's largest growth stocks had a sluggish start to 2026, but they're bouncing back. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
News headline image
Why Is Everyone Talking About Novo Nordisk? ↗
The drugmaker continues to face headwinds. 
Via The Motley Fool
News headline image
CVS Health Q2 Earnings Call Highlights ↗
CVS Health (NYSE:CVS) reported second-quarter results that exceeded its expectations, citing earnings growth across all operating segments and raising its full-year outlook for adjusted earnings per... 
Via MarketBeat
Topics Earnings
News headline image
Global Abemaciclib Market to Reach USD 3.18 Billion by 2034, Growing at 9.7% CAGR ↗
Global Abemaciclib Market to Reach USD 3.18 Billion by 2034, Growing at 9.7% CAGR According to the latest market intelligence from Intel Market Research, t 
Via Talk Markets
Topics Intellectual Property
SpaceX First-Quarter Print And A DeepMind Exit Split The Tape As Records Take A Breather ↗
Via Chartmill
News headline image
LLY Q2 Deep Dive: Key Products and Pipeline Expansion Offset Revenue Miss
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 47.7% year on year to ... 
Via StockStory
News headline image
Why Eli Lilly Stock Climbed Today ↗
Demand for the healthcare leader's weight-loss drugs continues to rise. 
Via The Motley Fool
News headline image
State Street XLV vs VanEck BBH: Which Healthcare ETF Is the Better Buy in 2026? ↗
XLV's lower costs and broader holdings delivered 30% more growth over five years, while BBH's concentrated biotech focus offers higher single-stock upside. 
Via The Motley Fool
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.